We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The National Medical Products Administration (NMPA) in China has agreed to review BeiGene’s supplemental new drug application (sNDA) of tislelizumab in urothelial carcinoma (UC).